Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory study of adjunctive brexpiprazole in MDD with anxiety
NCT02013531Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Nov 2013; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02013531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013531.